MX2015004039A - Composiciones de antibiotico de tazobactam arginina. - Google Patents
Composiciones de antibiotico de tazobactam arginina.Info
- Publication number
- MX2015004039A MX2015004039A MX2015004039A MX2015004039A MX2015004039A MX 2015004039 A MX2015004039 A MX 2015004039A MX 2015004039 A MX2015004039 A MX 2015004039A MX 2015004039 A MX2015004039 A MX 2015004039A MX 2015004039 A MX2015004039 A MX 2015004039A
- Authority
- MX
- Mexico
- Prior art keywords
- tazobactam arginine
- antibiotic compositions
- compositions
- arginine
- tazobactam
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000004475 Arginine Substances 0.000 title abstract 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title abstract 2
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 title abstract 2
- 229960003865 tazobactam Drugs 0.000 title abstract 2
- 230000003115 biocidal effect Effects 0.000 title 1
- -1 beta- lactam compound Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261706399P | 2012-09-27 | 2012-09-27 | |
| PCT/US2013/062256 WO2014052799A1 (en) | 2012-09-27 | 2013-09-27 | Tazobactam arginine antibiotic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015004039A true MX2015004039A (es) | 2015-10-29 |
Family
ID=50389002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015004039A MX2015004039A (es) | 2012-09-27 | 2013-09-27 | Composiciones de antibiotico de tazobactam arginina. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20150306076A1 (enExample) |
| EP (1) | EP2900244B1 (enExample) |
| JP (1) | JP6186001B2 (enExample) |
| KR (1) | KR102143256B1 (enExample) |
| CN (1) | CN105025901B (enExample) |
| AU (2) | AU2013323280A1 (enExample) |
| BR (1) | BR112015006868B1 (enExample) |
| CA (1) | CA2886402A1 (enExample) |
| IN (1) | IN2015DN03113A (enExample) |
| MX (1) | MX2015004039A (enExample) |
| RU (1) | RU2671485C2 (enExample) |
| WO (1) | WO2014052799A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140275000A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane pharmaceutical compositions |
| KR102329764B1 (ko) | 2013-03-15 | 2021-11-23 | 머크 샤프 앤드 돔 코포레이션 | 세프톨로잔 항균성 조성물 |
| US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
| US10376496B2 (en) | 2013-09-09 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
| US8906898B1 (en) * | 2013-09-27 | 2014-12-09 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
| KR101638311B1 (ko) * | 2016-02-29 | 2016-07-12 | (주)에프원테크놀로지 | 3축 코일 안테나의 단자부 및 이의 제조방법 |
| MX2017013433A (es) * | 2016-03-31 | 2018-01-30 | Wockhardt Ltd | Composiciones antibacterianas. |
| WO2017213944A1 (en) * | 2016-06-06 | 2017-12-14 | Merck Sharp & Dohme Corp. | Solid forms of ceftolozane and processes for preparing |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| EP4272831A3 (en) | 2018-08-09 | 2024-02-21 | Antabio SAS | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8323034D0 (en) * | 1983-08-26 | 1983-09-28 | Fujisawo Pharmaceutical Co Ltd | 7-substituted-3-vinyl-3-cephem compounds |
| JP2648750B2 (ja) * | 1988-03-02 | 1997-09-03 | 大塚化学株式会社 | β−ラクタム誘導体の製造方法 |
| AU679800B2 (en) * | 1993-11-06 | 1997-07-10 | Taiho Pharmaceutical Co., Ltd. | Crystalline penicillin derivative, and its production and use |
| CN1109688C (zh) | 1999-01-12 | 2003-05-28 | 中国药品生物制品检定所 | 他唑巴坦半水合物的制备与应用 |
| JP3743823B2 (ja) * | 2000-08-11 | 2006-02-08 | 大塚化学ホールディングス株式会社 | ペニシリン結晶及びその製造法 |
| JP3306473B1 (ja) * | 2001-05-01 | 2002-07-24 | 大塚化学株式会社 | β−ラクタム化合物の無水結晶及びその製造法 |
| JP2002338578A (ja) * | 2001-05-14 | 2002-11-27 | Otsuka Chem Co Ltd | β−ラクタム化合物の水和物結晶 |
| ATE368042T1 (de) | 2002-10-30 | 2007-08-15 | Astellas Pharma Inc | Cephemverbindungen |
| RS51506B (sr) * | 2004-12-02 | 2011-06-30 | Venus Remedies Limited H. O&R&D. | Smeše za suzbijanje beta-laktamazom posredovane rezistencije na antibiotike upotrebom inhibitora beta-laktamaze, korisne za injekcije |
| AU2006297289B2 (en) * | 2005-09-29 | 2013-03-21 | Novartis Ag | Antibiotic formulations, unit doses, kits, and methods |
| JP5852316B2 (ja) * | 2010-03-30 | 2016-02-03 | 富山化学工業株式会社 | ピペラシリン含有懸濁液の製造法 |
| US8476425B1 (en) * | 2012-09-27 | 2013-07-02 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine compositions |
| US20140275000A1 (en) * | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane pharmaceutical compositions |
| US8906898B1 (en) * | 2013-09-27 | 2014-12-09 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
-
2013
- 2013-09-27 US US14/431,878 patent/US20150306076A1/en not_active Abandoned
- 2013-09-27 CA CA2886402A patent/CA2886402A1/en active Pending
- 2013-09-27 BR BR112015006868-5A patent/BR112015006868B1/pt active IP Right Grant
- 2013-09-27 IN IN3113DEN2015 patent/IN2015DN03113A/en unknown
- 2013-09-27 CN CN201380061707.7A patent/CN105025901B/zh active Active
- 2013-09-27 KR KR1020157009612A patent/KR102143256B1/ko active Active
- 2013-09-27 EP EP13840550.1A patent/EP2900244B1/en active Active
- 2013-09-27 AU AU2013323280A patent/AU2013323280A1/en not_active Abandoned
- 2013-09-27 WO PCT/US2013/062256 patent/WO2014052799A1/en not_active Ceased
- 2013-09-27 RU RU2015115711A patent/RU2671485C2/ru active
- 2013-09-27 JP JP2015534749A patent/JP6186001B2/ja active Active
- 2013-09-27 MX MX2015004039A patent/MX2015004039A/es unknown
-
2014
- 2014-03-07 US US14/200,383 patent/US20140187528A1/en not_active Abandoned
- 2014-03-28 US US14/228,401 patent/US20140213567A1/en not_active Abandoned
- 2014-04-11 US US14/250,879 patent/US20140206659A1/en not_active Abandoned
-
2018
- 2018-05-30 AU AU2018203806A patent/AU2018203806B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140206659A1 (en) | 2014-07-24 |
| RU2671485C2 (ru) | 2018-11-01 |
| JP6186001B2 (ja) | 2017-08-23 |
| AU2018203806B2 (en) | 2020-04-02 |
| EP2900244A4 (en) | 2016-05-04 |
| BR112015006868A2 (pt) | 2017-07-04 |
| JP2015531378A (ja) | 2015-11-02 |
| CN105025901B (zh) | 2019-04-19 |
| BR112015006868B1 (pt) | 2021-11-30 |
| AU2013323280A1 (en) | 2015-04-09 |
| CN105025901A (zh) | 2015-11-04 |
| CA2886402A1 (en) | 2014-04-03 |
| US20150306076A1 (en) | 2015-10-29 |
| KR102143256B1 (ko) | 2020-08-11 |
| US20140187528A1 (en) | 2014-07-03 |
| RU2015115711A (ru) | 2016-11-20 |
| EP2900244B1 (en) | 2019-10-23 |
| EP2900244A1 (en) | 2015-08-05 |
| WO2014052799A1 (en) | 2014-04-03 |
| AU2018203806A1 (en) | 2018-06-21 |
| KR20150070156A (ko) | 2015-06-24 |
| US20140213567A1 (en) | 2014-07-31 |
| IN2015DN03113A (enExample) | 2015-10-02 |
| BR112015006868A8 (pt) | 2021-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03113A (enExample) | ||
| ZA201308066B (en) | Pharmaceutical compositions comprising beta-lactam antiboitic,sulbactam and beta-lactamase inhibitor | |
| IN2015DN00127A (enExample) | ||
| AU2015292632B2 (en) | Aldosterone synthase inhibitors | |
| MX2014007840A (es) | Dihidrodiazpinocarbazolonas tetra o penta-cicliclas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp). | |
| PH12015500263A1 (en) | New bicyclic derivatives | |
| EP3060041A4 (en) | Prostacyclin compounds, compositions and methods of use thereof | |
| IN2014DN09346A (enExample) | ||
| MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
| EP3037424A4 (en) | Novel quinoline-substituted compound | |
| AU2014227660A8 (en) | Ceftolozane antibiotic compositions | |
| EP3329919A8 (en) | Acc inhibitors and uses thereof | |
| IN2015DN00598A (enExample) | ||
| EP3082823A4 (en) | Iminothiadiazepane dioxide compounds as bace inhibitors, compositions, and their use | |
| EP3041841A4 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
| EP3043802A4 (en) | C5-spiro iminothiazine dioxides as bace inhibitors, compositions, and their use | |
| JO3318B1 (ar) | مثبطات bace | |
| AU2018253594A1 (en) | Dihydroxyphenyl neurotransmitter compounds, compositions and methods | |
| CA2875305C (en) | Fbxo3 inhibitors | |
| HK1222848A1 (zh) | 用作alk抑制剂的吡咯并三嗪 | |
| EP3186270A4 (en) | Cyclic urea compounds as granzyme b inhibitors | |
| EP3057968A4 (en) | Solid form of pyrazolopyridine compound | |
| EP3074049A4 (en) | Novel cell-penetrating compositions and methods using same | |
| MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. | |
| EP3026054A4 (en) | Hetero-condensed ring compound |